A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.
Uložené v:
| Vydané v: | The New England journal of medicine Ročník 389; číslo 1; s. 22 - 32 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
Massachusetts Medical Society
06.07.2023
|
| Predmet: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D. |
|---|---|
| Bibliografia: | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| ISSN: | 0028-4793 1533-4406 1533-4406 |
| DOI: | 10.1056/NEJMoa2213429 |